Psilocybin Clinical Trials
for Treatment Resistant Depression
Depression is the most common mental health condition in the general population. The World Health Organisation (WHO) has ranked depression as the 4th leading cause of disability worldwide with an estimated 322 million people currently living with depression (please refer to map below). Only 35% of depressed patients respond to current treatment options. A new way must be found.
Nov 22, 2019
The FDA grants Breakthrough Therapy designation to the Usona Institute for its psilocybin therapy for major depressive disorder.er.
Now having achieved double breakthrough therapy status with the FDA, numerous clinical trials worldwide irrefutably show the benefits of medicinal use of psilocybin when administered in the correct setting (for more information please click here).
We will build on this body of knowledge and collect data on how best to navigate mental health moving forward.
Worldwide incidence of depression
Psilocybin and Smoking Addictions
Psilocybin and End of Life Anxiety
MDMA and Post Traumatic Stress Disorder
Psilocybin in Exercise Sports Science
Exercise has proven to be one of the best methods to aid with depression. By using specific neurotropic compounds coupled with movement practices we will explore how these compounds effect areas of sports science.
We are building a Mental Health & Wellness Hospital which will provide an appropriate space for clinical research in this growing area.
Psilocybin in Meditation and
The power of meditation on mindfulness has been shows promise in changing epigenetic patterns.This is achieve by the stimulation of the Sigma-1 receptor.
43% of our DNA encodes for messenger RNA, (mRNA) - chemical signalling molecules.
We aim to prove clinically that psychedelics help facilitate deeper meditation experiences, and can modulate mRNA through epigenetic programing.
Deep states of meditation can be produced consistently with the correct dosage of psilocybin.
Alzheimers Prevalence and Severity
Psilocybin trials for the treatment of alzheimers is in the very early stages. However, there are promising leads shown via the way psilocybin interacts with brain chemistry to release neurotrophic growth factors (BDNF and GDNF) that are evolved in promoting survival of many types of neurons. We aim to develop medications to fight neuro-degenerative diseases.
Psilocybin is considered safe in clinical settings, and we will soon be conducting Alzheimers clinical studies with our compounds.
Links to Recent Clinical Trials